The Dish’s Weekly Biotechnology News Wrap Up – February 6, 2015
This week’s biotechnology news headlines include, Ebola news, Amgen’s biosimilar trial results, Bluebird’s blood disorder drug gets orphan status, Obama’s budget for precision medicine, Senate GOP looking for heath agency reforms, FDA approves Boehringer-Lilly drug for type-2 diabetes.
Cell Culture Events
February
Cell Line Development and Engineering – February 9-12, 2014, Dublin Ireland
http://www.informa-ls.com/event/Cellline
7th Annual Global Biomanufacturing Summit – February 18-20, 2015, Orange County, CA
With the affordable care act and added FDA pressure on companies to cut costs to the end user it has become imperative that the biological manufacturing industry optimizes and streamlines its processes in order to maintain profit margins and stay competitive.
The 7th Annual Global Biological Manufacturing Summit 2015 has been designed to enhance collaboration, discussion and networking amongst the Biological Manufacturing community.
The 2015 will programme will feature three dedicated streams, each tackling the latest challenges for the industry: Manufacturing, Supply chain, Quality and Regulation. Each stream will feature the most esteemed companies in their fields, including UCB, GSK, MEDIMMUNE GENENTECH, M W GROUP, KINAXIS.
Visit http://biomansummit.com for more information.
Book now via The Cell Culture Dish and save 15%
Cell Culture World Congress – February 23-25, 2015 –Munich Germany,
The region’s premier congress for the bioprocess industry. Where all major existing and emerging players obtain practical and technical outcomes to Bioprocessing and Biomanufacturing. Cell Culture World Congress is THE networking forum where pharma, biotech, academia and associated vendor stakeholders wanting to progress within the Cell Culture and Biomanufacturing market meet, debate and partner with those already strategically positioned.
50% off Cell Culture World Congress Attendance for Cell Culture Dish Readers by using the link below – https://secure.terrapinn.com/V5/rCalc.aspx?E=6871&R=NXJD
Downstream Processing World Congress – February 24-25, 2015 – Munich Germany
Technology and process optimization for pharma, biotech and CMOs. Co-located with Cell Culture World Congress, the event is THE genuine meeting place for bioprocess scientists to meet, source new technologies and share best practice.
50% off Downstream Processing World Congress Attendance for Cell Culture Dish Readers by using the link below –
https://secure.terrapinn.com/V5/rCalc.aspx?E=7159&R=PJQK
March
Introduction to Cell Culture Workshop – 4 days by BioSciConcepts
March 10-13, 2015
One of our most popular workshops, this Cell Culture Workshop covers essential fundamentals, providing a solid basis for the understanding of the growth of animal cells. We combine lecture and laboratory exercises aimed at giving participants a deeper understanding of serum-free media applications and related topics.
Topics include: Introduction to cell and tissue culture, serum containing media and the use of serum. cell counting and viability determination, development of growth curves, growth of adherent and suspension cells, transfection technologies for recombinant protein expression in animal cells, cryopreservation and cryothawing of animal cells, cell cloning , primary cell culture and so much more.
Genome Editing Applications – March 18-19, 2015 – Hilton Boston Back Bay, Boston MA
www.IBCLifeSciences.com/GenomeEditing
Biopharmaceutical Development and Production Week – March 30-April 2, 2015 – Hyatt Regency Huntington Beach Resort and Spa, Huntington Beach, CA (Co-located with Single-use Applications and Flexible Facilities)
http://www.ibclifesciences.com/BDPWeek/overview.xml
Headlines
“Trial finds GSK Ebola shot is safe and provokes immune response,” Reuters
“First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.”
If you like this story, please see our blog titled “Developing Ebola Vaccine and Securing Your Cold Chain Logistics Plan”
“Amgen biosimilar matches Humira in RA trial,” PharmaTimes
“Amgen’s biosimilar of Humira has shown comparable efficacy for moderate-to-severe rheumatoid arthritis in a late-stage trial with AbbVie’s branded inflammatory blockbuster”
If you like this story, please see our blog titled “The Benefits of Implementing Bioprocess Monitoring and Quality by Design in Process Development”
“BlueBird’s rare blood disorder drug gets breakthrough therapy status,” Reuters
“The U.S. Food and Drug Administration has designated BlueBird Bio Inc’s blood disorder drug a breakthrough therapy, speeding up the treatment’s development process.”
If you like this story, please see our blog titled “Small Molecules in Stem Cell Research”
“Obama Puts a Price on Precision Medicine,” Genetic Engineering News
“President Barack Obama’s administration will request $215 million for his precision medicine initiative in the budget he will propose next week for the federal fiscal year that starts October 1.”
If you like this story, please see our blog titled “Biologics Development: How do you Solve a Problem Like Data Management?”
“Blood from Ebola survivors could help spur new disease treatments,” Reuters
“After successfully treating four Ebola patients last year, Emory University in Atlanta is now leading a government-funded project that will use blood from survivors of the deadly virus to test a novel way of treating infectious disease.”
If you like this story, please see our blog titled “Stromal Cell Isolation from Adipose Tissue”
“Senate GOP eyes major reforms for health agencies,” The Hill
“Senate Republicans are pledging to reform two of the government’s largest health agencies as part of their effort to fix a medical industry that they say “takes too long and costs too much” to find new cures.”
If you like this story, please see our blog titled “Cool Tool – PureFlex Plus – A Robust Single Use Fluid Management Film for High Volume/Value Applications”
“FDA approves Boehringer-Lilly drug for type-2 diabetes patients,” Reuters
“The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said.”
If you like this story, please see our blog titled “The Top 20 Cell Culture Blogs of 2014”